Imidazo[2,1-f][1,6]naphthyridine, 2-[(1S,2S)-2-(5,8-dimethyl[1,2,4]triazolo[1,5-a]pyrazin-2-yl)cyclopropyl]-3-methyl-

Imidazo[2,1-f][1,6]naphthyridine, 2-[(1S,2S)-2-(5,8-dimethyl[1,2,4]triazolo[1,5-a]pyrazin-2-yl)cyclopropyl]-3-methyl- 구조식 이미지
카스 번호:
1516896-06-2
상품명:
Imidazo[2,1-f][1,6]naphthyridine, 2-[(1S,2S)-2-(5,8-dimethyl[1,2,4]triazolo[1,5-a]pyrazin-2-yl)cyclopropyl]-3-methyl-
동의어(영문):
SEP-0371845;SEP 0371845,SEP0371845;2-((1S,2S)-2-(5,8-Dimethyl-[1,2,4]triazolo[1,5-a]pyrazin-2-yl)cyclopropyl)-3-methylimidazo[2,1-f][1,6]naphthyridine;Imidazo[2,1-f][1,6]naphthyridine, 2-[(1S,2S)-2-(5,8-dimethyl[1,2,4]triazolo[1,5-a]pyrazin-2-yl)cyclopropyl]-3-methyl-
CBNumber:
CB53376893
분자식:
C21H19N7
포뮬러 무게:
369.42
MOL 파일:
1516896-06-2.mol

Imidazo[2,1-f][1,6]naphthyridine, 2-[(1S,2S)-2-(5,8-dimethyl[1,2,4]triazolo[1,5-a]pyrazin-2-yl)cyclopropyl]-3-methyl- 속성

밀도
1.52±0.1 g/cm3(Predicted)
산도 계수 (pKa)
5.38±0.50(Predicted)

안전

Imidazo[2,1-f][1,6]naphthyridine, 2-[(1S,2S)-2-(5,8-dimethyl[1,2,4]triazolo[1,5-a]pyrazin-2-yl)cyclopropyl]-3-methyl- C화학적 특성, 용도, 생산

Imidazo[2,1-f][1,6]naphthyridine, 2-[(1S,2S)-2-(5,8-dimethyl[1,2,4]triazolo[1,5-a]pyrazin-2-yl)cyclopropyl]-3-methyl- 준비 용품 및 원자재

원자재

준비 용품


Imidazo[2,1-f][1,6]naphthyridine, 2-[(1S,2S)-2-(5,8-dimethyl[1,2,4]triazolo[1,5-a]pyrazin-2-yl)cyclopropyl]-3-methyl- 공급 업체

글로벌( 7)공급 업체
공급자 전화 이메일 국가 제품 수 이점
TargetMol Chemicals Inc.
+1-781-999-5354
support@targetmol.com United States 19973 58
EnliPharma Technology Co., Ltd 0551-66399836 18955197623
sales@enlipharma.com China 1874 55
Shanghai Send Pharmaceutical Technology Co., Ltd. 021-58088081 Q2816483246
hailey@shsendpharm.com China 3139 55
Shanghai Rechem science Co., Ltd. 21-31433387 15618786686
sales@rechemscience.com China 2994 58
Beijing Jin Ming Biotechnology Co., Ltd. 010-60605840 18892239720
psaitong@jm-bio.com China 12308 58
Beijing Biocreative Technology Co., Ltd. 15522676233
3007606172@qq.com China 1249 58
TargetMol Chemicals Inc. 4008200310
marketing@tsbiochem.com China 24017 58

Copyright 2019 © ChemicalBook. All rights reserved